<DOC>
	<DOCNO>NCT00232453</DOCNO>
	<brief_summary>There establish standard preoperative treatment rectal cancer . Two large randomize study North America close lack accrual ; therefore method assess preoperative treatment rectal cancer Phase II study . This study build experience PMH gain two previous study demonstrate low expect toxicity concurrent 5FU infusion external radiotherapy . The current standard PMH preoperative radiation , 46Gy 23 fraction concurrent 5FU infusion 225mg/m2 . An increase radiation dose consequent increase chemotherapy may improve response rate , may also increase toxicity . It propose increase dose radiotherapy 50Gy 25 fraction concurrent chemotherapy measure acute toxicity complete remission rate .</brief_summary>
	<brief_title>Preoperative Combined Radiation Chemotherapy - Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Biopsy proven adenocarcinoma rectum Performance status &lt; 2 ( ECOG , appendix II ) Clinical Stage T2 N12 , T34 NO2 , without evidence distant metastasis Prior pelvic irradiation Inflammatory bowel disease Evidence distant metastasis Performance status &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>